Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.

Excerpts from the MY-COMPASSION Expert Meeting

30 Jan 2019
BTcP is defined as: “A transient exacerbation of pain that occurs either spontaneously, or in relation to a specific predictable or unpredictable trigger, despite relatively stable and adequately controlled background pain”.1,2 While there are various pain profiles associated with BTcP, a BTcP episode is typically severe, reaching peak pain intensity within 1–3 minutes from onset and is short in duration (ie, subsiding within 30 minutes).In Malaysia, opioids such as oral immediate-release(IR), intravenous (IV) and subcutaneous (SC) morphine are prescribed as ‘rescue’ medications for BTcP.2 IR opioids reach peak concentrations around 1 hour post-administration,and have a half-life of 3–6 hours, which may be suitable for longer duration BTcP episodes, but may not sufficiently address ‘sharp’, short-duration BTcP.2 In contrast, the faster onset of action seen in ROOs (eg, SLF which reaches peak plasma concentrations within 30–60 minutes post-administration) may be better suited for such episodes of BTcP.3,4

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 5 days ago
Progress in the treatment of rare cancers is named Advance of the Year by the American Society of Clinical Oncology (ASCO).
Jackey Suen, 08 Jul 2016

Scientists have refined anti-CD19 chimeric antigen receptor (CAR) T cell therapy, an investigational treatment for advanced non-Hodgkin’s lymphoma, with initial results showing significantly higher response and survival rates than the standard repertoire.